Post by
Trippedstocks on Feb 13, 2021 11:10am
UCSF - Medical Center
Dr. Fahy began working with RVV on Dec. 31, 2020. San Francisco had over 200 Hospitalized cases of Covid-19. Two weeks later there was about 160. On Jan 29 there was 122. At that same time there was about 50 cases in ICU with the larger ICU being at UCSF. On Jan 29. 20 in ICU at UCSF medical center. As well there would be 30 additional hospitalized patients at UCSF. Who is in charge of patient care in ICU at UCSF and would have significant influence (in the bay area) in standard care of hospitalized Covid-19 patients, not just at UCSF?
q "Dr. John Fahy, MD, MSc is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and the Department of Medicine at the University of California San Francisco and is a director of UCSFs severe asthma clinic. He also cares for critically ill patients in the intensive care units and directs the UCSF Airway Clinical Research Center."
Now with his known thiol research, he would most likely be willing to give a thiol drug to a patient. What drug and company have a IND EAP for a thiol drug? Dr. Fahy isn't just reviewing the clinical results, he IS the EAP.
Am I connecting dots?
https://www.latimes.com/projects/california-coronavirus-cases-tracking-outbreak/san-francisco-county/
Comment by
Chrisxd5 on Feb 13, 2021 11:26am
If these dots are correct then we are golden!!!
Comment by
rickydee on Feb 13, 2021 11:37am
This post has been removed in accordance with Community Policy
Comment by
alwaysoff on Feb 13, 2021 12:30pm
Totally awesome DD. Your post makes total sense. Onwards and upwards folks. Next few months are going to be very interesting. GLTA
Comment by
1ottrunner on Feb 13, 2021 3:04pm
Not a bad line of thinking, a stretch but a possibility. RVV would not have to complete the trial if the above turned out to be factual, even 10% would likely get it quickly through the FDA. The safety is proven.
Comment by
Chrisxd5 on Feb 13, 2021 6:26pm
I DONT LIKE YOU ANYMORE! Unless your wrong then ok
Comment by
Chrisxd5 on Feb 13, 2021 6:28pm
You ignoring this: The Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization.
Comment by
Chrisxd5 on Feb 13, 2021 6:43pm
I doubt that. Money was a issue but they were finishing up first interim. Needed more sites because overwhelmed with patients and then needed money "canacord" to help finance additional sites and complete up to 1000 patients. I think we will be hearing something sooner than you think. Again I could be wrong but from what I'm hearing it will be very soon